Medicare Part D

These toplines are part of a survey by the Kaiser Family Foundation and Harvard School of Public Health that examines public opinion on the Medicare prescription drug debate. The survey, a follow-up to a broader, more comprehensive survey released in June 2003 about the Medicare program and proposed changes, finds…

This survey, conducted by the Kaiser Family Foundation and Hewitt Associates between June and September 2003 provides detailed information on retiree health programs offered by large private-sector employers. The data in this survey reflect the responses of 408 large firms (private-sector employers with 1,000 or more workers) and provides information…

This chartpack is part of a survey by the Kaiser Family Foundation and Harvard School of Public Health that examines public opinion on the Medicare prescription drug debate. The survey, a follow-up to a broader, more comprehensive survey released in June 2003 about the Medicare program and proposed changes, finds…

This document, prepared by Health Policy Alternatives, Inc., provides a detailed side-by-side comparison of the prescription drug provisions of the Conference Agreement (H.R. 1) passed by the House and Senate in November 2003 and the House (H.R. 1) and Senate (S. 1) Medicare proposals passed in June 2003.Report (.pdf)

Standard Medicare Drug Benefit, 2006Out-of-pocket drug spending for Medicare beneficiaries under the standard Medicare drug benefit described in the Medicare Modernization Act of 2003. Chart (.pdf)

The Senate and House of Representatives each approved legislation in June of 2003 that would establish outpatient prescription drug coverage for Medicare beneficiaries as part of Medicare program reform. Among the key differences in the House and Senate bills that still must be addressed are the treatment of Medicaid beneficiaries…

Central to the current debate over Medicare prescription drug coverage is the role of private insurance plans in providing drug benefits to Medicare beneficiaries. This report offers views from health actuaries knowledgeable about the Medicare program and the prescription drug debate on key issues that emerge for potential plan sponsors,…

This testimony was delivered by Tricia Neuman, a vice president of the Kaiser Family Foundation, at a Senate Finance Committee hearing on the Bush Administration's Proposals for Medicare Modernization. The statement, which draws upon a report prepared for the Foundation by Health Policy Alternatives, Inc., provides an overview of existing…

This brief commissioned by the Foundation examines factors that contributed to Medicare’s lower-than-expected spending on prescription drugs under the Medicare Part D drug benefit that started in 2006. Since its launch, Medicare has spent about 30 percent less on Part D benefits than the Congressional Budget Office originally projected. Some…

This data spotlight examines the availability of gap coverage in the private Medicare Part D drug plans offered to beneficiaries in 2011, the first year of the phase-out of the gap, as required under the 2010 health reform law. The changes for 2011 include a 50 percent discount on brand-name…